4.3 Article

Increased viability of PC12 cells exposed to amyloid-β peptide by transduction with human TAT-methionine sulfoxide reductase

Journal

NEUROREPORT
Volume 14, Issue 18, Pages 2349-2353

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00001756-200312190-00012

Keywords

Alzheimer's disease; amyloid-beta; methionine sulfoxide reductase; MsrA transduction; TAT-MsrA

Categories

Ask authors/readers for more resources

Methionine sulfoxide reductase (MsrA) catalyzes the reduction of methionine sulfoxide to methionine, which is able to scavenge oxidatively damaged proteins. Oxidative stress has been linked to the pathophysiology of Alzheimer's disease, and a decrease in MsrA activity has also been implicated in Alzheimer's disease. The transactivator of transcription (TAT) protein from human immunodeficiency virus I has been used to deliver full-length proteins into mammalian cells. We produced genetic in-frame TAT-MsrA fusion protein and successfully transduced it into PCl2 cells, where it showed enzymatic activity. We showed that transduction of TAT-MsrA increased cell viability and reduced DNA fragmentation in PCl2 cells treated with amyloid-beta (Abeta). We suggest that MsrA transduction could reduce the oxidative damage caused to cellular proteins by Abeta and could play a role in the treatment of Alzheimer's disease. (C) 2003 Lippincott Williams Wilkins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available